New study tests taking migraine pill at earliest warning signs
NCT ID NCT07310290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether taking ubrogepant (a migraine medication) during the earliest phase of a migraine—called the prodrome—can prevent moderate to severe headache pain. About 189 adults who already use ubrogepant will take it as usual and report their symptoms over 13 weeks. The goal is to see if early treatment can stop a migraine attack before it fully develops.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chicago Headache Center & Research Inst /ID# 272345
RECRUITINGNaperville, Illinois, 60563, United States
-
Neurology and Pain Specialty Center /ID# 278508
RECRUITINGAliso Viejo, California, 92656, United States
-
Tri City Research Center, LLC /ID# 278800
RECRUITINGGrand Island, Nebraska, 68803, United States